| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net income (loss) | 44,806 | 26,371 |
| Depreciation and amortization expense | 1,087 | 703 |
| Share-based compensation expense | 26,768 | 16,624 |
| Non-cash lease expense | 2,703 | 1,759 |
| Net amortization of premiums and accretion of discounts on short-term investments | -14 | 589 |
| Net gain on disposal of property and equipment | 67 | 24 |
| Deferred income taxes | 9,864 | 5,637 |
| Prepaid expenses and other current assets | 10,165 | 12,195 |
| Accounts receivable, net | 10,018 | -9,814 |
| Inventory | 15,032 | 21,817 |
| Other long-term assets | -1,832 | -1,975 |
| Accounts payable | 4,264 | 6,992 |
| Accrued expenses, accrued collaboration expenses and other current liabilities | 17,870 | 9,502 |
| Operating lease liabilities | -2,537 | -1,777 |
| Other long-term liabilities | 12,702 | 7,439 |
| Net cash provided by operating activities | 84,091 | 50,414 |
| Purchases of property and equipment | 935 | 264 |
| Purchases of short-term investments | 275,953 | 129,793 |
| Proceeds from the maturities of short-term investments | 158,709 | 74,633 |
| Net cash used in investing activities | -118,179 | -55,424 |
| Proceeds from issuance of class a ordinary shares under incentive award plans and employee share purchase plan | 32,177 | 15,925 |
| Payments in connection with ordinary shares tendered for employee tax obligations | 6,812 | 2,459 |
| Net cash provided by financing activities | 25,365 | 13,466 |
| Net decrease in cash and cash equivalents | -8,723 | 8,456 |
| Cash and cash equivalents at beginning of period | 183,581 | - |
| Cash and cash equivalents at end of period | 174,858 | - |
Kiniksa Pharmaceuticals International, plc (KNSA)
Kiniksa Pharmaceuticals International, plc (KNSA)